arrow
A

Amélie Lusque

oncopole claudius regaud
H指数:26
被引数:4,491

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer

药物耐受细胞中持久的TOP1切割复合物驱动肺癌对EGFR靶向疗法的适应性耐药

2026-09-230
OA
sWGS Identifies a Copy-Number-High Subset of TP53-mutated Multiple-Classifier Endometrial Carcinomas With Adverse Clinicopathological Features

sWGS鉴定出TP53突变型多分类器子宫内膜癌中具有不良临床病理特征的拷贝数高亚群

2026-09-170
OAAI
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer

BRCA1/2、PALB2基因突变与HR+转移性乳腺癌中一线CDK4/6抑制剂疗效

2026-02-160
OAAI
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score® in node-positive breast cancer: independent validation in the PACS-01 trial.

将预测内分泌治疗敏感性(SET2,3指数)与复发风险评分®相结合在淋巴结阳性乳腺癌中的应用:PACS-01试验的独立验证。

2025-12-010
PRE
TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

免疫检查点抑制剂治疗的晚期黑色素瘤患者的TNF特征: 来自melanf α 临床研究的结果

2025-03-010
OAAI
Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial

揭示曲妥珠单抗德鲁替康(T-DXd)的作用机制和耐药机制:DAISY试验的补充生物标志物分析

2024-09-010
PRE
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma

单个循环肿瘤细胞中的突变分析描绘了黑色素瘤的肿瘤内异质性

2024-06-191
PRE
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
2023-07-24130
OAAI